Results 21 to 30 of about 6,459 (257)

New Drug: Tirzepatide (Mounjaro™)

, 2023
Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and is a chronic and progressive illness. Millions of Americans have T2DM and many patients do not achieve the recommended blood glucose levels.
Gettman, Lana, Pharm.D.
core   +1 more source

Tirzepatide adds hepatoprotection to its armoury

, 2022
In The Lancet Diabetes & Endocrinology, Gastaldelli and colleagues present their findings from the SURPASS-3 MRI, a substudy of the randomised, open-label, parallel-group, phase-3 SURPASS-3 trial (1).
Giovanni Targher, Targher, Giovanni
core   +1 more source

Tirzepatide: First Approval

, 2022
   Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the ...
Yahiya Y. Syed (6594444)
core   +1 more source

Tirzepatide to treat diabetes and obesity.

, 2023
reservedQuesto lavoro di tesi propone di fornire una descrizione dettagliata di entrambe le patologie, diabete ed obesità, con relative cure e trattamenti ponendo particolare attenzione al nuovo farmaco tirzepatide.This thesis work aims to provide a ...
MANZATI, SOFIA
core  

Tirzepatide reduces appetite, energy intake and fat mass in people with T2D

, 2023
   OBJECTIVE: To evaluate effects of tirzepatide on body composition, appetite and energy intake to address the potential mechanisms involved in body weight loss with tirzepatide.
Julia Dunn (829425), Jing Li (7435754), Kieren J. Mather (9194696), Axel Haupt (4821168), Chrisanthi A. Karanikas (333497), J Hans DeVries (58716), Melissa K. Thomas (713074), Tamer Coskun (297154), Shweta Urva (14526769), Edward J. Pratt (3330429), Zvonko Milicevic (9714382), Tim Heise (227695)   +11 more
core   +1 more source

A new therapeutic class for type 2 diabetes: Tirzepatide a new double agonist of GIP and GLP-1 receptors

, 2022
openLa tirzepatide è una singola molecola che combina il doppio agonismo dei recettori del polipetide insulinotropico glucosio dipendente (GIP) e del peptide-1 simile al glucagone (GLP-1).
FRANCHINI, MATTEO
core  

Adipocyte‐Derived Leptolin Enhances Energy Expenditure and Prevents Obesity

Advanced Science, EarlyView.
We identified a novel adipokine, which we named leptolin. In humans, leptolin levels in white adipose tissue were positively correlated with exercise and negatively associated with body mass index. We observed elevated leptolin in serum from athletes and lower leptolin in serum from obese individuals.
Jiarui Liu, Bingwei Wang, Zhijie Su, Xiaoxv Han, Miao He, Yun Zhao, Yujia Hou, Daotong Li, Weiguang Zhang, Lihua Qin, Ke Wang, Yanchun Li, Yi Yan, Siwang Yu, Xiaoshuai Huang, Tairan Yuwen, Jianyuan Luo, Ruimao Zheng   +17 more
wiley   +1 more source

Gut Microbiota, Immunity, and Metabolism in the Progression From Chronic Liver Disease to Hepatocellular Carcinoma

Advanced Science, EarlyView.
This review explains how chronic liver injury progresses toward hepatocellular carcinoma through interconnected changes in gut microbes, metabolism, immunity, fibrosis, and diet. It highlights microbial metabolites, bile‐acid signaling, immune dysfunction, and nutritional or microbiome‐based interventions as opportunities to identify risk earlier ...
Yi Hu, Caiyan Lin, Lijie Zhang, Xue Jiang, Huawen Li, Yangzhe Wu   +5 more
wiley   +1 more source

Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes

Kidney Medicine
Rationale & Objective: Tirzepatide, a dual GIP/GLP-1 receptor agonist, has been approved for type 2 diabetes (T2D) and obesity. However, the real-world utilization of tirzepatide remains unexplored, particularly in patients with chronic kidney ...
Panupong Hansrivijit, Janinne Ortega-Montiel, Deborah J. Wexler, Elisabetta Patorno, Julie M. Paik   +4 more
doaj   +1 more source

Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats

Frontiers in Pharmacology, 2023
Background: One of the typical symptoms of diabetes mellitus patients was memory impairment, which was followed by gradual cognitive deterioration and for which there is no efficient treatment.
Xiying Guo, Min Lei, Jiangyan Zhao, Min Wu, Zhanhong Ren, Xiaosong Yang, Changhan Ouyang, Xiufen Liu, Chao Liu, Qingjie Chen   +9 more
doaj   +1 more source